Select highlightsMay 8, 2025SID Conference: BTK DataAccess posterJanuary 12, 2026News: REX-8756 Phase 1 MilestoneRead moreJanuary 12, 2026News: Financing from Institutional Investors & LillyRead more Corporate presentationDownload May 2026 Presentation Latest press releasesJune 12, 2026Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) CongressesRead moreMay 18, 2026Recludix Pharma to Present at RBC Capital Markets Global Healthcare ConferenceRead moreMay 15, 2026Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic DermatitisRead moreApril 30, 2026Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual MeetingRead more More press releases Events & presentationsJune 2, 2026Jefferies Global Healthcare ConferenceRead moreMay 20, 2026RBC Capital Markets Global Healthcare ConferenceAccess webcastMay 15, 2026REX-8756 is an Oral, First-in-Class Orthosteric STAT6 Inhibitor That Demonstrates Efficacious Potential and Safety Differentiation in a Th2-Mediated Dermatitis ModelView posterJune 30, 2025Recludix Platform has Unlocked Development of Oral, Reversible Small Molecule Inhibitors of SH2 DomainsView poster More events & presentations News coverage highlightsAugust 7, 2023BioCentury: Recludix: targeting STATs via their SH2 domainsRead moreJuly 20, 2023BioWorld: Recludix enters a potential $1.2B deal with SanofiRead moreJuly 20, 2023SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix Read moreJuly 20, 2023Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical programRead moreJuly 20, 2023Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with RecludixRead more
